Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunocore Holdings Plc ADR (NQ: IMCR )

47.76 -0.10 (-0.21%)
Streaming Delayed Price Updated: 1:06 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunocore Holdings Plc ADR

< Previous 1 2 3 Next >
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Immunocore to present four posters at AACR Annual Meeting 2023
From Immunocore Holdings Limited
Via Globe NewsWire
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Preview: Immunocore Holdings's Earnings
 
Via Benzinga
Immunocore Reveals First Data From HIV Infection Candidate Study
 
Via Benzinga
Immunocore Reports 2022 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via Globe NewsWire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via Globe NewsWire
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
From Immunocore Holdings Limited
Via Globe NewsWire
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
From Immunocore Holdings Limited
Via Globe NewsWire
Analyst Ratings for Immunocore Hldgs
 
Via Benzinga
Where Immunocore Hldgs Stands With Analysts
 
Via Benzinga
7 Analysts Have This to Say About Immunocore Hldgs
 
Via Benzinga
Biotech's Drug Pipeline Expands From Melanoma To Other Cancers
Immunocore is the IBD Stock of the Day as the biotech company expands its pipeline. Earnings For IMCR stock are due in March. 
Via Investor's Business Daily
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via Globe NewsWire
3 Pharma Stocks That Will Mint Millionaires
These pharma stocks all have excellent risk-reward ratios and the companies have developed treatments that could easily become blockbusters. 
Via InvestorPlace
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
From Immunocore Holdings Limited
Via Globe NewsWire
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings Limited
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
 
Via Benzinga
Immunocore is awarded the Prix Galien France award for KIMMTRAK
From Immunocore Holdings Limited
Via Globe NewsWire
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
From Immunocore Holdings Limited
Via Globe NewsWire
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
From Immunocore Holdings Limited
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022
 
Via Benzinga
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
From Immunocore Holdings Limited
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 50 stocks hit new 52-week highs. 
Via Benzinga
Procter & Gamble To Jump Over 16%? Here Are 5 Other Price Target Changes For Monday
 
Via Benzinga
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust. 
Via Benzinga
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
From Immunocore Holdings Limited
Via Globe NewsWire
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.